2.605
price down icon1.70%   -0.045
 
loading
Immunitybio Inc stock is traded at $2.605, with a volume of 1.15M. It is down -1.70% in the last 24 hours and down -3.52% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.65
Open:
$2.65
24h Volume:
1.15M
Relative Volume:
0.13
Market Cap:
$2.29B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.6856
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-3.87%
1M Performance:
-3.52%
6M Performance:
-17.56%
1Y Performance:
-52.03%
1-Day Range:
Value
$2.60
$2.6729
1-Week Range:
Value
$2.60
$3.11
52-Week Range:
Value
$1.83
$7.48

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
671
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IBRX
Immunitybio Inc
2.60 2.52B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.51 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
555.00 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
592.94 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
300.80 31.54B 3.81B -644.79M -669.77M -6.24

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-20-25 Upgrade Piper Sandler Neutral → Overweight
Mar-06-25 Initiated H.C. Wainwright Buy
Jan-10-25 Initiated BTIG Research Buy
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
Jul 28, 2025

Natural Killer Cell Therapies Clinical Trials, Companies, - openPR.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does ImmunityBio Inc. compare to its industry peersDiscover breakthrough investment opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What is ImmunityBio Inc. company’s growth strategyMaximize your portfolio’s growth with expert tips - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is ImmunityBio Inc. a growth stock or a value stockCapitalize on emerging market opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

When is ImmunityBio Inc. stock expected to show significant growthInvest confidently with professional market insights - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What institutional investors are buying ImmunityBio Inc. stockAchieve breakthrough performance in the market - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-28 00:26:40 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How ImmunityBio Inc. stock reacts to Fed policy changesShort Term Profit Focus - metal.it

Jul 27, 2025
pulisher
Jul 25, 2025

ImmunityBio’s Stock Soars: Buy or Sell? - timothysykes.com

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio (IBRX) Secures $80M Through Direct Offering | IBRX S - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - BioSpace

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio announces $80M registered direct offering - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about ImmunityBio Inc. stockHigh-yield investments - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Lelezard

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio Announces $80 Million Securities Purchase - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio's Q2 Preliminary Revenue: A Strategic Inflection Point in the Biotech Immune Therapeutics Sector - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio (IBRX) Achieves Significant Revenue Growth in Q2 2025 | IBRX Stock News - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

ImmunityBio's Q2 Earnings and Revenue Growth: Assessing the Path to Sustainable Value Creation - AInvest

Jul 25, 2025
pulisher
Jul 24, 2025

Is ImmunityBio Inc. a good long term investmentMarket-leading profit generation - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - MSN

Jul 24, 2025
pulisher
Jul 22, 2025

What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga

Jul 22, 2025
pulisher
Jul 21, 2025

ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha

Jul 21, 2025
pulisher
Jul 20, 2025

ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView

Jul 15, 2025
pulisher
Jul 14, 2025

ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView

Jul 14, 2025
pulisher
Jul 12, 2025

ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha

Jul 12, 2025
pulisher
Jul 11, 2025

ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks

Jul 11, 2025
pulisher
Jul 10, 2025

Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN

Jul 10, 2025
pulisher
Jul 09, 2025

ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

Jul 08, 2025
pulisher
Jul 07, 2025

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard

Jul 07, 2025

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.68
price down icon 1.78%
$37.00
price down icon 0.16%
$102.73
price up icon 0.99%
$27.03
price down icon 1.09%
$111.86
price down icon 0.82%
biotechnology ONC
$301.76
price up icon 2.26%
Cap:     |  Volume (24h):